Rice Hall James & Associates’s MoonLake Immunotherapeutics MLTX Stock Holding History

Rice Hall James & Associates’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.58M	Buy	183,801 +16,035	+10%	+$291K	0.17%	132
2026 Q1	$3.13M	Buy	167,766 +40,301	+32%	+$668K	0.17%	126
2025 Q4	$1.68M	Sell	127,465 -7,370	-5%	-$87K	0.09%	173
2025 Q3	$967K	Sell	134,835 -7,485	-5%	-$390K	0.05%	206
2025 Q2	$6.72M	Buy	142,320 +4,804	+3%	+$196K	0.36%	69
2025 Q1	$5.37M	Buy	137,516 +26,383	+24%	+$1.14M	0.32%	69
2024 Q4	$6.02M	Buy	111,133 +35,664	+47%	+$1.82M	0.33%	69
2024 Q3	$3.81M	Buy	+75,469	New	+$3.54M	0.21%	110

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Rice Hall James & Associates's MLTX Position: Q2 2026 in Review

Rice Hall James & Associates increased its MoonLake Immunotherapeutics (MLTX) stake by 9.6% in Q2 2026, buying an estimated $291K and bringing the position to 183,801 shares worth $3.58M. The position accounts for 0.17% of the portfolio, ranked #132.

Rice Hall James & Associates first reported a position in MLTX in Q3 2024 and has held it in 8 quarters since. The position peaked at $6.72M in Q2 2025. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

Rice Hall James & Associates held 183,801 shares of MoonLake Immunotherapeutics worth $3.58M as of Q2 2026.
Rice Hall James & Associates bought 16,035 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $291K.
MoonLake Immunotherapeutics made up 0.17% of Rice Hall James & Associates's portfolio in Q2 2026, its #132 holding.
Rice Hall James & Associates first reported a position in MoonLake Immunotherapeutics in Q3 2024 and has held it in 8 quarters since.
Rice Hall James & Associates's MoonLake Immunotherapeutics position peaked at $6.72M in Q2 2025.
173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Rice Hall James & Associates's 13F filing for Q2 2026, filed 7 Aug 2026.